| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a SOMPS, Salpêtrière Hospital, Department of Medical Oncology, Paris, France; b Centre Charlebourg, la Garenne-Colombes, France
Correspondence: Gerald Auclerc, M.D., Salpêtrière Hospital, Department of Medical Oncology, 47 Boulevard de l'Hôpital, 75013 Paris, France. Telephone: 33-1-4216-0474; Fax: 33-1-4336-4841.
Most cases of advanced carcinoma of the prostate are hormonosensitive. The use of combined androgen blockade (CAB) seems to improve survival and quality of life, but only when combined with chemical castration by luteinizing-hormone-releasing hormone analog and without the use of steroidal antiandrogens. After CAB, further hormonal treatments remain efficacious, such as antiandrogen withdrawal followed by estrogens, aromatase inhibitors, and hormone-refractory prostate cancer multiple cytotoxic agents. For painful bone lesions, external beam radiotherapy, biphosphonates, and strontium 89 or samarium 153 provide pain relief. The use of new methods for the evaluation of response and quality of life will allow the rapid identification of effective treatments and permit powered phase III trials.
This article has been cited by other articles:
![]() |
T K JOENSUU, S NILSSON, A R HOLMBERG, M MARQUEZ, M TENHUNEN, T SAARTO, and H JOENSUU Phase I Trial on sms-D70 Somatostatin Analogue in Advanced Prostate and Renal Cell Cancer Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 361 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Di Lorenzo, G. Tortora, F. P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, et al. Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3438 - 3444. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Weihua, R. Lathe, M. Warner, and J.-A. Gustafsson An endocrine pathway in the prostate, ERbeta , AR, 5alpha -androstane-3beta ,17beta -diol, and CYP7B1, regulates prostate growth PNAS, October 15, 2002; 99(21): 13589 - 13594. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Dixon, K. B. Knopf, and W. D. Figg The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |